RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Deol, A. K., French, M. D., & Webster, J. P. (2020). Schistosomiasis and the global goals reply. New England Journal of Medicine, 382(16), 1575-1576. https://doi.org/10.1056/nejmc2002117
To the Editor: Tait et al. (Dec. 19 issue)(1) report that the M72/AS01(E) vaccine had an efficacy of 50% against pulmonary tuberculosis disease in a phase 2B trial after 3 years of follow-up, a result that represents the first tuberculosis vaccine in a century that has had significant efficacy. M72/AS01(E) was evaluated in three countries: South Africa, Kenya, and Zambia. In the vaccine group, 13 cases of tuberculosis occurred, and in the placebo group 26 cases occurred. An important note of caution, however, is that the number of persons tested - and consequently the number of cases counted - was . . .
